Sodium–Glucose Co-transporter 2 Inhibitors and Cardiovascular Event Reduction in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
European Cardiology Review · 03.07.2026
DOI: 10.15420/ecr.2025.67 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 03.07.2026. Verfasst von Asaad Hussein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Ankara Yıldırım Beyazit University Ankara, Turkey. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure with preserved ejection fraction (HFpEF) is a prevalent and challenging cardiovascular condition associated with high morbidity and mortality. Despite the lack of effective pharmacological treatments, recent studies have suggested that sodium–glucose co-transporter 2 inhibitors (SGLT2Is) may offer potential benefits in reducing cardiovascular events in HFpEF patients. The aim of this systematic review and meta-analysis is to assess the efficacy of SGLT2Is in reducing cardiovascular outcomes in individuals with HFpEF.
Methods
A comprehensive literature search was conducted across PubMed, Cochrane Library, Embase, and clinical trial registries for studies published up to October 2024. Randomised controlled trials (RCTs) that investigated the use of SGLT2Is in patients with HFpEF and reported on major cardiovascular outcomes were included. Data from eligible studies were pooled to calculate risk ratios (RR) and 95% CIs for the primary outcomes, including major adverse cardiovascular events (MACE) and hospitalisation for heart failure (HHF).
Results
Fifteen RCTs involving 12,436 patients with HFpEF were included in the meta-analysis. Treatment with SGLT2Is reduced the risk of MACE (RR=0.79, 95% CI [0.70–0.89]) and HHF (RR=0.72, 95% CI [0.65–0.87]) compared with placebo. Secondary analyses demonstrated reductions in cardiovascular mortality (RR=0.84, 95% CI [0.75–0.95]) and improvements in health-related quality of life as assessed by Kansas City Cardiomyopathy Questionnaire scores.
Conclusion
SGLT2Is significantly reduce cardiovascular events, including HHF and MACE, in patients with HFpEF. These findings support the growing evidence for the use of SGLT2Is as a promising therapeutic option in this high-risk patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Ankara Yıldırım Beyazit University Ankara, Turkey.
- Department of Molecular Medicine, University of Pavia Pavia, Italy.
- Kasturba Medical College, Manipal Academy of Higher Education Karnataka, India.
- Faculty of Medicine, Medical University of Plovdiv Plovdiv, Bulgaria.
- Department of Medicine and Pharmacy, Nicolae Testemițanu State University Chisinau, Moldova.
- Department of Pharmacy, University of Huddersfield Huddersfield, UK.
ORCID-Profile: Asaad Hussein, Mohammad Eisa Ali, Venkata Kanishk Yannakula, Maleeha Pandit, Pinhas Harel, George Alan Kadungamparambil, Motassam Ali
Zitieren
APA
Hussein, A., Ali, M. E., Yannakula, V. K., Pandit, M., Harel, P., Kadungamparambil, G. A., & Ali, M. (2026). Sodium–Glucose Co-transporter 2 Inhibitors and Cardiovascular Event Reduction in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. European Cardiology Review. https://doi.org/10.15420/ecr.2025.67
Vancouver
Hussein A, Ali ME, Yannakula VK, Pandit M, Harel P, Kadungamparambil GA, et al. Sodium–Glucose Co-transporter 2 Inhibitors and Cardiovascular Event Reduction in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. European Cardiology Review. 2026. doi:10.15420/ecr.2025.67
BibTeX
@article{Hussein2026,
author = {Hussein, Asaad and Ali, Mohammad Eisa and Yannakula, Venkata Kanishk and Pandit, Maleeha and Harel, Pinhas and Kadungamparambil, George Alan and Ali, Motassam},
title = {Sodium–Glucose Co-transporter 2 Inhibitors and Cardiovascular Event Reduction in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis},
journal = {European Cardiology Review},
year = {2026},
doi = {10.15420/ecr.2025.67}
}
EUVIMED